Cargando…
Pasireotide-resistant Refractory Cushing's Disease without Somatostatin Receptor 5 Expression
Pasireotide, which has a high affinity for somatostatin receptor (SSTR) 5, has attracted attention as a new treatment for refractory Cushing's disease. The patient was a 28-year-old man. He had refractory Cushing's disease and underwent multiple surgeries, radiotherapy, and medication ther...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8943369/ https://www.ncbi.nlm.nih.gov/pubmed/34471015 http://dx.doi.org/10.2169/internalmedicine.6314-20 |
_version_ | 1784673502489477120 |
---|---|
author | Mizuno, Tomoko Inoshita, Naoko Fukuhara, Noriaki Tatsushima, Keita Takeshita, Akira Yamada, Shozo Nishioka, Hiroshi Takeuchi, Yasuhiro |
author_facet | Mizuno, Tomoko Inoshita, Naoko Fukuhara, Noriaki Tatsushima, Keita Takeshita, Akira Yamada, Shozo Nishioka, Hiroshi Takeuchi, Yasuhiro |
author_sort | Mizuno, Tomoko |
collection | PubMed |
description | Pasireotide, which has a high affinity for somatostatin receptor (SSTR) 5, has attracted attention as a new treatment for refractory Cushing's disease. The patient was a 28-year-old man. He had refractory Cushing's disease and underwent multiple surgeries, radiotherapy, and medication therapy. An examination of the adenoma by immunohistochemistry revealed a low SSTR5 expression. An USP8 mutation was not detected by reverse transcription polymerase chain reaction. Although we administered pasireotide, it was ineffective. While a further investigation is necessary, the analysis of SSTR5 expression may support the prediction of the efficiency of pasireotide for Cushing's disease. We report this case as a useful reference when considering whether or not to use pasireotide for refractory corticotroph adenomas. |
format | Online Article Text |
id | pubmed-8943369 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Japanese Society of Internal Medicine |
record_format | MEDLINE/PubMed |
spelling | pubmed-89433692022-04-14 Pasireotide-resistant Refractory Cushing's Disease without Somatostatin Receptor 5 Expression Mizuno, Tomoko Inoshita, Naoko Fukuhara, Noriaki Tatsushima, Keita Takeshita, Akira Yamada, Shozo Nishioka, Hiroshi Takeuchi, Yasuhiro Intern Med Case Report Pasireotide, which has a high affinity for somatostatin receptor (SSTR) 5, has attracted attention as a new treatment for refractory Cushing's disease. The patient was a 28-year-old man. He had refractory Cushing's disease and underwent multiple surgeries, radiotherapy, and medication therapy. An examination of the adenoma by immunohistochemistry revealed a low SSTR5 expression. An USP8 mutation was not detected by reverse transcription polymerase chain reaction. Although we administered pasireotide, it was ineffective. While a further investigation is necessary, the analysis of SSTR5 expression may support the prediction of the efficiency of pasireotide for Cushing's disease. We report this case as a useful reference when considering whether or not to use pasireotide for refractory corticotroph adenomas. The Japanese Society of Internal Medicine 2021-08-31 2022-03-01 /pmc/articles/PMC8943369/ /pubmed/34471015 http://dx.doi.org/10.2169/internalmedicine.6314-20 Text en Copyright © 2022 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Case Report Mizuno, Tomoko Inoshita, Naoko Fukuhara, Noriaki Tatsushima, Keita Takeshita, Akira Yamada, Shozo Nishioka, Hiroshi Takeuchi, Yasuhiro Pasireotide-resistant Refractory Cushing's Disease without Somatostatin Receptor 5 Expression |
title | Pasireotide-resistant Refractory Cushing's Disease without Somatostatin Receptor 5 Expression |
title_full | Pasireotide-resistant Refractory Cushing's Disease without Somatostatin Receptor 5 Expression |
title_fullStr | Pasireotide-resistant Refractory Cushing's Disease without Somatostatin Receptor 5 Expression |
title_full_unstemmed | Pasireotide-resistant Refractory Cushing's Disease without Somatostatin Receptor 5 Expression |
title_short | Pasireotide-resistant Refractory Cushing's Disease without Somatostatin Receptor 5 Expression |
title_sort | pasireotide-resistant refractory cushing's disease without somatostatin receptor 5 expression |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8943369/ https://www.ncbi.nlm.nih.gov/pubmed/34471015 http://dx.doi.org/10.2169/internalmedicine.6314-20 |
work_keys_str_mv | AT mizunotomoko pasireotideresistantrefractorycushingsdiseasewithoutsomatostatinreceptor5expression AT inoshitanaoko pasireotideresistantrefractorycushingsdiseasewithoutsomatostatinreceptor5expression AT fukuharanoriaki pasireotideresistantrefractorycushingsdiseasewithoutsomatostatinreceptor5expression AT tatsushimakeita pasireotideresistantrefractorycushingsdiseasewithoutsomatostatinreceptor5expression AT takeshitaakira pasireotideresistantrefractorycushingsdiseasewithoutsomatostatinreceptor5expression AT yamadashozo pasireotideresistantrefractorycushingsdiseasewithoutsomatostatinreceptor5expression AT nishiokahiroshi pasireotideresistantrefractorycushingsdiseasewithoutsomatostatinreceptor5expression AT takeuchiyasuhiro pasireotideresistantrefractorycushingsdiseasewithoutsomatostatinreceptor5expression |